Prism will be used by Healthcare Providers to enhance standard of care clinical outcomes. Prism uses an Amygdala-fMRI-guided model for processing EEG signals. Prism uses several electrodes EEG-signal to produce a real time Amygdala-derived-EFP biomarker signal to train patients in downregulating the Amygdala-derived-EFP biomarker during neurofeedback.

Butterflly is a digital therapeutics company focused on safe, evidenced-based, highly personalized, and de-stigmatized behavioral health. Users leverage person-generated data and the therapeutic power of peer groups inside secure social media-style private networks. Extended services also include coaching and telehealth therapy.

Our first-to-market solution, Prism for PTSD, is a promising software as a medical device for the treatment of PTSD as an adjunct to standard of care. About 250 million people worldwide live with PTSD, yet treatments are lacking and often lead to side effects that may last a lifetime. Prism for PTSD: An adjunct to standard of care therapy, was validated in a multi-center clinical trial in 5 medical centers in the USA and in Israel. While using Prism, patients learn to downregulate the amygdala-derived-EFP signal and how to control their PTSD symptoms under the supervision of a healthcare provider.

We deliver culturally-centered, intersectional and evidence-based care for teens and adults from all walks of life while also providing an alternative to in-person therapy that is more affordable and accessible.